Literature DB >> 21785038

mTOR inhibition and erythropoiesis: microcytosis or anaemia?

Fritz Diekmann1, Jordi Rovira, Maribel Diaz-Ricart, Edgar Marcelo Arellano, Barbara Vodenik, Josep Maria Jou, Joan Lluís Vives-Corrons, Gines Escolar, Josep M Campistol.   

Abstract

BACKGROUND: Anaemia and microcytosis are common post kidney transplantation. The aim of this study was to evaluate the potential role of mammalian target of rapamycin (mTOR) inhibition in the development of anaemia and microcytosis in healthy animals and in human erythroid cultures in vitro.
METHODS: Rats with normal kidney function were treated with sirolimus (n = 7) or vehicle (n = 8) for 15 weeks. Hemograms were determined thereafter. In the sirolimus withdrawal part of the study, rats received sirolimus (SRL) for 67 days (n = 4) 1 mg/kg three times per week or for 30 days (n = 4) and were observed until Day 120. Hemograms were performed regularly. Peripheral blood mononuclear cells from healthy controls (HC; n = 8), kidney transplant patients with sirolimus treatment with (SRL + MC; n = 8) or without microcytosis (SRL - MC; n = 8) were isolated and cultured in the absence or presence of SRL (5 ng/mL).
RESULTS: SRL-treated animals had a reduced mean corpuscular volume (MCV) and elevated erythrocyte count compared with control animals after 15 weeks of treatment. This effect was evident as early as 4 weeks (MCV: 61.5 ± 1.8 versus 57 ± 1.7 fL; P = 0.0156; Red blood count 7.4 ± 0.3 × 10(9)/L versus 8.6 ± 0.5 × 10(9)/L; P = 0.0156) and was reversible 90 days after SRL withdrawal. SRL in the culture medium of erythroid cultures led to fewer colonies in cultures from HC as well as from kidney transplant patients (without SRL: 34.2 ± 11.4 versus with SRL: 27.5 ± 9.9 BFU-E-derived colonies P = 0.03), regardless if the cultures were derived from recipients with normocytic or with microcytic erythrocytes. The presence of tacrolimus in the culture medium had no influence on the number and size of colonies.
CONCLUSION: mTOR inhibition induces microcytosis and polyglobulia, but not anaemia in healthy rats. This might be caused by growth inhibition of erythroid precursor cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21785038     DOI: 10.1093/ndt/gfr318

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  15 in total

1.  The mTORC1/4E-BP pathway coordinates hemoglobin production with L-leucine availability.

Authors:  Jacky Chung; Daniel E Bauer; Alireza Ghamari; Christopher P Nizzi; Kathryn M Deck; Paul D Kingsley; Yvette Y Yien; Nicholas C Huston; Caiyong Chen; Iman J Schultz; Arthur J Dalton; Johannes G Wittig; James Palis; Stuart H Orkin; Harvey F Lodish; Richard S Eisenstein; Alan B Cantor; Barry H Paw
Journal:  Sci Signal       Date:  2015-04-14       Impact factor: 8.192

Review 2.  mTOR inhibitors and renal allograft: Yin and Yang.

Authors:  Gianluigi Zaza; Simona Granata; Paola Tomei; Valentina Masola; Giovanni Gambaro; Antonio Lupo
Journal:  J Nephrol       Date:  2014-05-08       Impact factor: 3.902

3.  FOXO3-mTOR metabolic cooperation in the regulation of erythroid cell maturation and homeostasis.

Authors:  Xin Zhang; Genís Campreciós; Pauline Rimmelé; Raymond Liang; Safak Yalcin; Sathish Kumar Mungamuri; Jeffrey Barminko; Valentina D'Escamard; Margaret H Baron; Carlo Brugnara; Dmitri Papatsenko; Stefano Rivella; Saghi Ghaffari
Journal:  Am J Hematol       Date:  2014-07-22       Impact factor: 10.047

4.  Rapamycin extends murine lifespan but has limited effects on aging.

Authors:  Frauke Neff; Diana Flores-Dominguez; Devon P Ryan; Marion Horsch; Susanne Schröder; Thure Adler; Luciana Caminha Afonso; Juan Antonio Aguilar-Pimentel; Lore Becker; Lillian Garrett; Wolfgang Hans; Moritz M Hettich; Richard Holtmeier; Sabine M Hölter; Kristin Moreth; Cornelia Prehn; Oliver Puk; Ildikó Rácz; Birgit Rathkolb; Jan Rozman; Beatrix Naton; Rainer Ordemann; Jerzy Adamski; Johannes Beckers; Raffi Bekeredjian; Dirk H Busch; Gerhard Ehninger; Jochen Graw; Heinz Höfler; Martin Klingenspor; Thomas Klopstock; Markus Ollert; Jörg Stypmann; Eckhard Wolf; Wolfgang Wurst; Andreas Zimmer; Helmut Fuchs; Valérie Gailus-Durner; Martin Hrabe de Angelis; Dan Ehninger
Journal:  J Clin Invest       Date:  2013-07-25       Impact factor: 14.808

Review 5.  Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors.

Authors:  Gianluigi Zaza; Paola Tomei; Paolo Ria; Simona Granata; Luigino Boschiero; Antonio Lupo
Journal:  Clin Dev Immunol       Date:  2013-09-19

6.  miR-144/451 represses the LKB1/AMPK/mTOR pathway to promote red cell precursor survival during recovery from acute anemia.

Authors:  Xiao Fang; Feiyang Shen; Christophe Lechauve; Peng Xu; Guowei Zhao; Jacobi Itkow; Fan Wu; Yaying Hou; Xiaohui Wu; Lingling Yu; Huiqing Xiu; Mengli Wang; Ruiling Zhang; Fangfang Wang; Yanqing Zhang; Daxin Wang; Mitchell J Weiss; Duonan Yu
Journal:  Haematologica       Date:  2017-12-21       Impact factor: 9.941

Review 7.  Drug-Induced Hematological Cytopenia in Kidney Transplantation and the Challenges It Poses for Kidney Transplant Physicians.

Authors:  Muhammad Abdul Mabood Khalil; Muhammad Ashhad Ullah Khalil; Taqi F Taufeeq Khan; Jackson Tan
Journal:  J Transplant       Date:  2018-08-01

8.  mTOR Inhibition improves anaemia and reduces organ damage in a murine model of sickle cell disease.

Authors:  Jintao Wang; Jennifer Tran; Hui Wang; Chiao Guo; David Harro; Andrew D Campbell; Daniel T Eitzman
Journal:  Br J Haematol       Date:  2016-03-31       Impact factor: 8.615

9.  A critical role for mTORC1 in erythropoiesis and anemia.

Authors:  Zachary A Knight; Sarah F Schmidt; Kivanc Birsoy; Keith Tan; Jeffrey M Friedman
Journal:  Elife       Date:  2014-09-08       Impact factor: 8.140

Review 10.  Longevity, aging and rapamycin.

Authors:  Dan Ehninger; Frauke Neff; Kan Xie
Journal:  Cell Mol Life Sci       Date:  2014-11       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.